Capital Fund Management S.A. Eagle Pharmaceuticals, Inc. Transaction History

Capital Fund Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$41.72 - $51.34 $777,827 - $957,182	-18,644 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$37.02 - $51.28 $1.1 Million - $1.52 Million	-29,728 Reduced 61.46%	18,644 $791,000
Q2 2020 Aug 13, 2020	SELL	$43.24 - $55.02 $1.22 Million - $1.55 Million	-28,138 Reduced 36.78%	48,372 $2.32 Million
Q1 2020 May 13, 2020	BUY	$34.37 - $60.07 $962,909 - $1.68 Million	28,016 Added 57.77%	76,510 $3.52 Million
Q4 2019 Feb 13, 2020	BUY	$54.32 - $64.31 $1.98 Million - $2.34 Million	36,459 Added 302.94%	48,494 $2.91 Million
Q3 2019 Nov 13, 2019	BUY	$53.25 - $59.98 $640,863 - $721,859	12,035 New	12,035 $681,000
Q2 2018 Aug 14, 2018	SELL	$51.25 - $76.62 $730,722 - $1.09 Million	-14,258 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$52.16 - $66.86 $1.8 Million - $2.31 Million	-34,589 Reduced 70.81%	14,258 $751,000
Q4 2017 Feb 09, 2018	SELL	$49.6 - $60.87 $3.8 Million - $4.67 Million	-76,683 Reduced 61.09%	48,847 $2.61 Million
Q3 2017 Nov 13, 2017	BUY	$46.62 - $60.36 $5.85 Million - $7.58 Million	125,530	125,530 $7.49 Million

8.59M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $10M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.